Agnes Shanley


Former Team Biologics Inspector's Whistleblower Complaint Raises Questions About Support and Training

A former Team Biologics' whistleblower’s complaint raises questions about FDA inspector training and support, as well as GMP noncompliance patterns at biologics facilities.

Tufts’ New Figures on Drug-Development Costs Spark Debate

Tufts research suggests costs to launch a new drug have doubled since 2003, but some question conclusions.